首页> 外文期刊>Gastrointestinal Endoscopy >Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled trials
【24h】

Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled trials

机译:Indomethacin和Diclofenac在预防ERCP后胰腺炎:治疗前瞻性对照试验的系统审查和荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Background and Aims: Diclofenac and indomethacin are the most studied drugs for preventing post-ERCP pancreatitis (PEP). However, there are no prospective, randomized multicenter trials with a sufficient number of patients for correct evaluation of their efficacy. Our aim was to evaluate all prospective trials published in full text that studied the efficacy of diclofenac or indomethacin and were controlled with placebo or non-treatment for the prevention of PEP in adult patients undergoing ERCP.
机译:背景和目的:双氯芬酸和吲哚美辛是预防ERCP后胰腺炎(PEP)的最多药物。 然而,没有前瞻性,随机的多中心试验,具有足够数量的患者,用于正确评估它们的疗效。 我们的宗旨是评估全文发布的所有前瞻性试验,这些预期试验研究了Diclofenac或Indomethacin的疗效,并在接受ERCP的成年患者中预防PEP的安慰剂或非治疗控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号